Copper chelation selectively kills colon cancer cells through redox cycling and generation of reactive oxygen species
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central Ltd.
Abstract
Background: Metals including iron, copper and zinc are essential for physiological processes yet can be toxic at high concentrations. However the role of these metals in the progression of cancer is not well defined. Here we study the anti-tumor activity of the metal chelator, TPEN, and define its mechanism of action.Methods: Multiple approaches were employed, including cell viability, cell cycle analysis, multiple measurements of apoptosis, and mitochondrial function. In addition we measured cellular metal contents and employed EPR to record redox cycling of TPEN-metal complexes. Mouse xenografts were also performed to test the efficacy of TPEN in vivo.Results: We show that metal chelation using TPEN (5μM) selectively induces cell death in HCT116 colon cancer cells without affecting the viability of non-cancerous colon or intestinal cells. Cell death was associated with increased levels of reactive oxygen species (ROS) and was inhibited by antioxidants and by prior chelation of copper. Interestingly, HCT116 cells accumulate copper to 7-folds higher levels than normal colon cells, and the TPEN-copper complex engages in redox cycling to generate hydroxyl radicals. Consistently, TPEN exhibits robust anti-tumor activity in vivo in colon cancer mouse xenografts.Conclusion: Our data show that TPEN induces cell death by chelating copper to produce TPEN-copper complexes that engage in redox cycling to selectively eliminate colon cancer cells. © 2014 Fatfat et al.; licensee BioMed Central Ltd.
Description
Keywords
Colon cancer, Copper, Metal chelation, Reactive oxygen species, Redox cycling, Tpen, Animals, Antioxidants, Apoptosis, Cell line, tumor, Chelating agents, Colonic neoplasms, Ethylenediamines, Female, Hct116 cells, Ht29 cells, Humans, Mice, Mice, scid, Neoplasms, experimental, Oxidation-reduction, Xenograft model antitumor assays, Antioxidant, Hydroxyl radical, N,n,n',n' tetrakis(2 pyridylmethyl)ethylenediamine, Reactive oxygen metabolite, Zinc, Chelating agent, Ethylenediamine derivative, N,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine, Animal experiment, Animal model, Animal tissue, Article, Cancer inhibition, Cell viability, Chelation, Controlled study, Drug cytotoxicity, Drug efficacy, Drug selectivity, Hct116 cell line, Human, Human cell, In vivo study, Intestine cell, Mouse, Nonhuman, Oxidation reduction reaction, Tumor xenograft, Animal, Drug effects, Drug screening, Ht 29 cell line, Metabolism, Pathology, Scid mouse, Tumor cell line